[161Tb]Tb-曲妥珠单抗在HER2表达乳腺癌中的体内研究:高肿瘤摄取与肿瘤生长抑制
本研究在人表皮生长因子受体2(HER2)表达乳腺癌小鼠模型中评估[161Tb]Tb-曲妥珠单抗的体内分布、耐受性和疗效。SPECT/CT显示注射后72小时肿瘤摄取峰值超过10 %ID/g组织,10 MBq剂量耐受良好且显著抑制肿瘤生长(P = 0.0007),支持其作为HER2表达癌症的潜在治疗选择。
要点
- 功能化与放射性标记不影响结合亲和力,免疫反应分数为89%。
- SPECT/CT显示注射后72小时肿瘤摄取峰值,高剂量组肿瘤摄取超过10 %ID/g组织。
- 10 MBq剂量耐受良好,治疗后104天肿瘤体积显著小于对照组(P = 0.0007)。
核心结论
- 功能化和放射性标记未影响结合亲和力,[161Tb]Tb-曲妥珠单抗在HER2表达肿瘤中显示高肿瘤摄取(>10 %ID/g组织),峰值在72小时。
- 剂量高达10 MBq的[161Tb]Tb-曲妥珠单抗耐受良好,并高效抑制肿瘤生长(P = 0.0007),支持其作为HER2表达癌症的有吸引力的治疗选择。
研究设计与样本
- 研究将曲妥珠单抗通过非位点特异性偶联功能化DOTA并标记161Tb,进行体外结合亲和力和免疫反应性测定。
- 在皮下BT474肿瘤小鼠中,注射20 MBq [161Tb]Tb-曲妥珠单抗(三种比活度)后4、24、72、168小时进行SPECT/CT成像评估质量剂量对生物分布的影响。
- 耐受性评估使用递增剂量5、10、20 MBq,疗效比较[161Tb]Tb-曲妥珠单抗与载体、曲妥珠单抗和曲妥珠单抗德鲁替康组。
主要发现
- 功能化和放射性标记的放射化学产率为97% ± 2%,放射化学纯度高于99%。
- 功能化和天然曲妥珠单抗的结合亲和力分别为0.83和0.39 nM,免疫反应分数为89%。
- SPECT/CT显示注射后72小时肿瘤摄取峰值,0.5、0.05和0.005 MBq/µg剂量组的肿瘤摄取分别为10.8 ± 1.1、12.8 ± 2.2和6.3 ± 0.03 %ID/g组织。
- 20 MBq [161Tb]Tb-曲妥珠单抗显示放射毒性,而5和10 MBq耐受良好。
- 10 MBq [161Tb]Tb-曲妥珠单抗治疗后104天肿瘤体积显著小于载体组(P = 0.0007)。
关键数值与推荐
- 放射化学产率97% ± 2%,放射化学纯度>99%。
- 结合亲和力:功能化曲妥珠单抗0.83 nM,天然曲妥珠单抗0.39 nM;免疫反应分数89%。
- 肿瘤摄取峰值在72小时,剂量0.5、0.05、0.005 MBq/µg组分别为10.8 ± 1.1、12.8 ± 2.2、6.3 ± 0.03 %ID/g组织。
- 耐受剂量:5和10 MBq耐受良好,20 MBq显示放射毒性。
- 疗效:10 MBq组治疗后104天肿瘤体积显著小于载体组(P = 0.0007)。
临床怎么用
- 在HER2表达乳腺癌模型中,[161Tb]Tb-曲妥珠单抗10 MBq剂量耐受良好且显著抑制肿瘤生长,支持进一步临床转化研究。
- SPECT/CT成像可用于评估[161Tb]Tb-曲妥珠单抗的生物分布和肿瘤摄取,注药后72小时为肿瘤摄取峰值时间点。
局限性
- 研究仅在小鼠皮下BT474肿瘤模型中进行,结果外推到人类需谨慎。
- 原文未报告长期生存数据或临床毒性详细评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human epidermal growth factor receptor 2 (HER2) has emerged as attractive for targeted radionuclide therapy of HER2-expressing breast cancer. The present study aimed to investigate the image-derived biodistribution, tolerability, and efficacy of [161Tb]Tb-trastuzumab as a potential therapeutic alternative or supplement to trastuzumab and trastuzumab deruxtecan in HER2-expressing tumors. Methods: Trastuzumab was functionalized with DOTA by non-site-specific conjugation and radiolabeled with 161Tb. In vitro assays were performed to evaluate binding affinity and immunoreactivity of [161Tb]Tb-trastuzumab. The influence of mass dose on the biodistribution of [161Tb]Tb-trastuzumab was assessed in mice bearing subcutaneous BT474 tumors by SPECT/CT imaging performed 4, 24, 72, and 168 h after injection of 20 MBq of [161Tb]Tb-trastuzumab labeled at 3 specific activities. Tolerability was evaluated with escalating doses of 5, 10, and 20 MBq of [161Tb]Tb-trastuzumab, and the efficacy of [161Tb]Tb-trastuzumab was compared with that of the vehicle, trastuzumab, and trastuzumab deruxtecan groups. Results: Functionalization and radiolabeling resulted in a radiochemical yield of 97% ± 2% and a radiochemical purity above 99%. The binding affinity of functionalized and native trastuzumab was 0.83 and 0.39 nM, respectively, with an immunoreactive fraction of 89%. SPECT/CT imaging demonstrated peak tumor uptake 72 h after injection, with tumor uptake of 10.8 ± 1.1, 12.8 ± 2.2, and 6.3 ± 0.03 %ID/g of tissue for mice dosed with 0.5, 0.05, and 0.005 MBq/µg, respectively. Radiotoxicity was evident in mice dosed with 20 MBq of [161Tb]Tb-trastuzumab, whereas 5 and 10 MBq of [161Tb]Tb-trastuzumab were well tolerated. Antitumor efficacy was observed in mice dosed with 10 MBq of [161Tb]Tb-trastuzumab, which presented tumor volumes statistically significantly smaller than those of the vehicle group 104 d after treatment (P = 0.0007). Conclusion: Functionalization and radiolabeling did not affect binding affinity. Biodistribution of [161Tb]Tb-trastuzumab revealed high tumor uptake of more than 10 %ID/g of tissue, peaking at 72 h. [161Tb]Tb-trastuzumab in doses of up to 10 MBq was tolerated and highly effective at inhibiting tumor growth (P = 0.0007). These results support the potential of [161Tb]Tb-trastuzumab as an attractive treatment option for HER2-expressing cancers.
引用
- Cold S, Sadasivam P, Wessel MM, et al. In Vivo Studies of [161Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2-Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression. J Nucl Med. 2026. PMID: 41679917. doi:10.2967/jnumed.125.269741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。